An interventional study of CardioPrevent® Program in Pre-Eclampsia, sponsored by University of Calgary. Status unknown. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.
Sponsored by University of Calgary · Not applicable, Interventional, and Other
IMPROVE is a pilot RCT with a behavioral intervention component (CardioPrevent program). The primary objectives of this pilot study are to assess the feasibility of the implementation of a postpartum CVD prevention lifestyle program in women with a HDP as well as the transferability and fidelity of the Ottawa-based CardioPrevent® program to a centre in Calgary (following a "Train the Trainer" model). Secondary objectives include an initial evaluation of the effectiveness of this intervention on clinical outcomes and measures of microvascular function between study arms at one year.
Background and Rationale
Cardiovascular disease (CVD) (i.e., coronary artery disease, stroke, and peripheral arterial disease) is one of the leading causes of morbidity and mortality in Canada, particularly amongst women. Women with hypertensive disorders of pregnancy (HDP) represent one of the highest-risk populations for premature CVD and CVD mortality. The 2011 American Heart Association (AHA) Guidelines on the prevention of CVD in women now include HDP as an independent CVD risk factor in the evaluation of CVD risk. To achieve "ideal cardiovascular health" targets, healthy lifestyle modifications are suggested as first-line therapy, with pharmacotherapy as second line. The immediate postpartum period may be an early window of opportunity for early upstream CVD prevention, capitalizing on a woman's increased motivation to improve her health. Despite these recommendations and opportunity for early CVD prevention, there is little published data, and, in particular, there are no randomized controlled trials (RCT) assessing the short-term or long-term effectiveness of lifestyle interventions in women with HDP.
To address this important clinical problem and knowledge gap, the interdisciplinary IMPROVE team adapted the evidence-based University of Ottawa Heart Institute CardioPrevent® Lifestyle program to proactively address the unique barriers to, and facilitators of behaviour change in early postpartum women with HDP. Prior to undertaking a widespread evaluation of CardioPrevent® in a CVD prevention study for women with HDP, a pre-assessment of the feasibility of this postpartum lifestyle program using this research approach through a pilot study is essential. In addition, this pilot study will provide important information on CardioPrevent®'s effectiveness on modifying clinically-important cardiovascular-related clinical outcomes and novel, non-invasive measures of microvascular function in early postpartum women with HDP to inform the design of a larger CVD prevention study. This pilot RCT will be the first to assess the feasibility and effects of a one-year postpartum-specific CVD prevention lifestyle program in women with a HDP.
Research Questions \& Objectives
The primary objectives of this pilot study are to assess the feasibility of the implementation of a postpartum CVD prevention lifestyle program in women with a HDP as well as the transferability and fidelity of the Ottawa-based CardioPrevent® program to a centre in Calgary (following a "Train the Trainer" model). Secondary objectives include: an initial evaluation of the effectiveness of this intervention on clinical outcomes and measures of microvascular function between study arms at one year.
Study Design: A 2-year, single centre, single-blind, pilot randomized controlled trial (RCT).
Study Population (Inclusion/Exclusion Criteria): Women with a HDP (i.e., preeclampsia, eclampsia or gestational hypertension) delivering at the Foothills Medical Centre will be invited to participate. Women with pre-existing chronic hypertension, diabetes (type 1 or type 2), kidney disease or cardiovascular disease (coronary artery, cerebrovascular and peripheral arterial) will be excluded.
Intervention: CardioPrevent® Program - a one year, evidence-based cardiovascular prevention program that consists of 25 contacts (either in person or by phone) with a trained behaviour change counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
Control: Standard clinical postpartum care. All Participants: Participants in both arms will receive educational material about the risk of CVD and CVD prevention for women with HDP from the Preeclampsia Foundation.
Sample size: A total of 84 women will be recruited (42 in each arm). Recruitment \& Retention: There are over 7000 deliveries per year at the FMC. Using a conservative estimate of 7% prevalence of HDP (as it is a tertiary care referral centre), approximately 245 women (10 per week) will have HDP over our 6-month recruitment period. The investigators anticipate recruiting 2-3 eligible women per week to reach the target sample size in 6 months. To minimize loss to follow-up, they plan to use participant incentives such as covering the costs of parking and childcare.
Exclusion Criteria:
Participants in the control arm will receive standard postpartum clinical care through the participants' usual healthcare providers. No intervention will be administered. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
In addition to standard care, participants randomized to the intervention arm will also receive the CardioPrevent® Program. This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
Behavioral: CardioPrevent® Program
This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
Study feasibility - recruitment
Acceptance of the study by women with HDP (i.e., feasibility) measured by recruitment rate of ≥ 20% over a 6-month time period (as per weekly recruitment logs).
Time frame: 2 years
Study feasibility - adherence
Acceptance of the study by women with HDP (i.e., feasibility) measured by participant adherence of ≥ 80% to the lifestyle program (i.e., 20/25 contacts with counsellor completed).
Time frame: 2 years
Study feasibility - study completion
Acceptance of the study by women with HDP (i.e., feasibility) measured by overall study completion rate of ≥ 75% of participants.
Time frame: 2 years
Study feasibility - participant satisfaction
Acceptance of the study by women with HDP (i.e., feasibility) measured by participant satisfaction score of ≥ fair on the Client Satisfaction Questionnaire at the end of study.
Time frame: 2 years
Implementation and fidelity of CardioPrevent® at the University of Calgary (a second centre) - audits
Implementation and fidelity of CardioPrevent® at the University of Calgary (a second centre) measured by standardized audits.
Time frame: 2 years
Implementation and fidelity of CardioPrevent® at the University of Calgary (a second centre) - clinical outcomes
Implementation and fidelity of CardioPrevent® at the University of Calgary (a second centre) measured by similar clinical outcomes between sites.
Time frame: 2 years
Weight
Comparison of weight (kg) between both study arms at one year of follow-up.
Time frame: 2 years
Body mass index (BMI)
Comparison of BMI (kg/m\^2) between both study arms at one year of follow-up.
Time frame: 2 years
Waist-to-hip ratio
Comparison of waist-to-hip ratio between both study arms at one year of follow-up .
Time frame: 2 years
Smoking status
Comparison of smoking status between both study arms at one year of follow-up (CO levels \<10ppm confirmatory for non-smoking).
Time frame: 2 years
Postpartum depression
Comparison of postpartum depression between both study arms at one year of follow-up (measured by the Edinburgh Postnatal Depression Scale).
Time frame: 2 years
Blood pressure
Comparison of blood pressure (mmHg) between both study arms at one year of follow-up.
Time frame: 2 years
Fasting lipids
Comparison of fasting lipids (mmol/L) between both study arms at one year of follow-up.
Time frame: 2 years
Fasting glucose
Comparison of fasting glucose (mmol/L) between both study arms at one year of follow-up.
Time frame: 2 years
HbA1C
Comparison of HbA1C (%) between both study arms at one year of follow-up.
Time frame: 2 years
Urine albumin to creatinine ratio
Comparison of urine albumin to creatinine ratio between both study arms at one year of follow-up.
Time frame: 2 years
Metabolic syndrome
Comparison of metabolic syndrome between both study arms at one year of follow-up measured by z-score (calculated using Adult Treatment Panel (ATP) III Criteria for Metabolic Syndrome).
Time frame: 2 years
CVD risk
Comparison of CVD risk between both study arms at one year of follow-up.
Time frame: 2 years
Microvascular function - flow mediated dilation (FMD)
Comparison of FMD between both study arms at one year of follow-up.
Time frame: 2 years
Microvascular function - brachial artery hyperemic velocity
Comparison of brachial artery hyperemic velocity between both study arms at one year of follow-up.
Time frame: 2 years
Microvascular function - peripheral arterial tonometry (PAT)
Comparison of PAT between both study arms at one year of follow-up.
Time frame: 2 years
Changes in amount of physical activity recorded in questionnaire
Comparison of amount of physical activity (IPAQ short form) logs between both study arms at one year of follow-up.
Time frame: 2 years
Changes in amount of physical activity recorded in activity logs
Comparison of amount of physical activity (physical activity logs) logs between both study arms at one year of follow-up.
Time frame: 2 years
Changes in amount of physical activity captured by accelerometer
Comparison of amount of physical activity (accelerometer data) between both study arms at one year of follow-up.
Time frame: 2 years
Changes in dietary behavior
Comparison of eating behaviors (Rapid eating assessment of patients) questionnaire between both study arms at one year of follow-up.
Time frame: 2 years
Changes in nutrient status
Comparison of nutrient status (measured by three days of prospective food logs) between both study arms at one year of follow-up.
Time frame: 2 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Calgary